{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:49:59Z","timestamp":1711586999381},"posted":{"date-parts":[[2024,1,2]]},"group-title":"In Review","reference-count":53,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p><jats:bold>Background:<\/jats:bold> Effective xanthine oxidoreductase inhibition (XOI) urate-lowering treatment (ULT) to target significantly reduces gout flare burden and synovitis between 1-2 years therapy, without clearing all monosodium urate crystal deposits. Paradoxically, treat to target ULT is associated with increased flare activity for at least 1 year in duration on average, before gout flare burden decreases. Since XOI has anti-inflammatory effects, we tested for biomarkers of sustained, effective ULT that alters gouty inflammation.\n<jats:bold>Methods:<\/jats:bold> We characterized the proteome of febuxostat-treated murine bone marrow macrophages. Blood samples (baseline and 48 weeks ULT) were analyzed by unbiased proteomics in febuxostat and allopurinol ULT responders from two, independent, racially and ethnically distinct comparative effectiveness trial cohorts (n=19, n=30). STRING-db and multivariate analyses supplemented determinations of significantly altered proteins via Wilcoxon matched pairs signed rank testing.\n<jats:bold>Results:<\/jats:bold> The proteome of cultured IL-1b-stimulated macrophages revealed febuxostat-induced anti-inflammatory changes, including for classical and alternative pathway complement activation pathways. At 48 weeks ULT, with altered purine metabolism confirmed by serum metabolomics, serum urate dropped &gt;30%, to normal (&lt;6.8 mg\/dL) in all the studied patients. Overall, flares declined from baseline. Treated gout patient sera and peripheral blood mononuclear cells (PBMCs) showed significantly altered proteins (p&lt;0.05) in clustering and proteome networks. CRP was not a useful therapy response biomarker. By comparison, significant serum proteome changes included decreased complement C8 heterotrimer C8A and C8G chains essential for C5b-9 membrane attack complex assembly and function; increase in the NLRP3 inflammasome activation promoter vimentin; increased urate crystal phagocytosis inhibitor sCD44; increased gouty inflammation pro-resolving mediator TGFB1; decreased phagocyte-recruiting chemokine PPBP\/CXCL7, and increased monocyte\/macrophage-expressed keratin-related proteins (KRT9,14,16) further validated by PBMC proteomics. STRING-db analyses of significantly altered serum proteins from both cohorts revealed a tight interactome network including central mediators of gouty inflammation (eg, IL-1B, CXCL8, IL6, C5).\n<jats:bold>Conclusions:<\/jats:bold> Rewiring of inflammation mediators in a tight serum protein interactome was a biomarker of sustained XOI-based ULT that effectively reduced serum urate and gout flares. Monitoring of the serum and PBMC proteome, including for changes in the complement pathway could help determine onset and targets of anti-inflammatory changes in response to effective, sustained XOI-based ULT.\nTrial Registration: ClinicalTrials.gov Identifier: NCT02579096<\/jats:p>","DOI":"10.21203\/rs.3.rs-3770277\/v1","type":"posted-content","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:53:36Z","timestamp":1704221616000},"source":"Crossref","is-referenced-by-count":0,"title":["Sustained xanthine oxidase inhibitor treat to target urate lowering therapy rewires a tight inflammation serum protein interactome"],"prefix":"10.21203","author":[{"given":"Concepcion","family":"Sanchez","sequence":"first","affiliation":[{"name":"University of California San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamika","family":"Campeau","sequence":"additional","affiliation":[{"name":"University of California San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Liu-Bryan","sequence":"additional","affiliation":[{"name":"University of California San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Mikuls","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"O'Dell","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"University of California San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[{"name":"University of California San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"Dalbeth N","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039\u20132052. doi: 10.1016\/S0140-6736(16)00346-9.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41927-019-0075-6","article-title":"The challenges of gout flare reporting: mapping flares during a randomized controlled trial","volume":"3","author":"Teoh N","year":"2019","unstructured":"Teoh N, Gamble GD, Horne A, Taylor WJ, Palmano K, Dalbeth N. The challenges of gout flare reporting: mapping flares during a randomized controlled trial. BMC Rheumatol. 2019;3:27. doi:https:\/\/doi.org\/10.1186\/s41927-019-0075-6.","journal-title":"BMC Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1136\/annrheumdis-2011-201215","article-title":"Purine-rich foods intake and recurrent gout attacks","volume":"71","author":"Zhang Y","year":"2012","unstructured":"Zhang Y, Chen C, Choi H, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis. 2012;71:1448\u201353. doi:10.1136\/annrheumdis-2011-201215.","journal-title":"Ann Rheum Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12916-017-0922-5","article-title":"What makes gouty inflammation so variable?","volume":"15","author":"Terkeltaub R","year":"2017","unstructured":"Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017;15:158. doi:10.1186\/s12916-017-0922-5.","journal-title":"BMC Med"},{"issue":"4","key":"ref5","doi-asserted-by":"publisher","first-page":"101723","DOI":"10.1016\/j.berh.2021.101723","article-title":"Role of diet in hyperuricemia and gout","volume":"35","author":"Danve A","year":"2021","unstructured":"Danve A, Sehra ST, Neogi T. Role of diet in hyperuricemia and gout. Best Pract Res Clin Rheumatol. 2021;35(4):101723. doi:10.1016\/j.berh.2021.101723.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald JD","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72:744\u2013760. doi:10.1002\/acr.24180.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette P","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342. doi:10.1136\/annrheumdis-2016-209707.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41584-021-00725-9","article-title":"Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care","volume":"18","author":"Choi HK","year":"2022","unstructured":"Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol. 2022;18(2):97\u2013111. doi: 10.1038\/s41584-021-00725-9.","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"ard-2023-224731","DOI":"10.1136\/ard-2023-224731","article-title":"Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial","volume":"31","author":"Stamp L","unstructured":"Stamp L, Horne A, Mihov B, Drake J, Haslett J, Chapman PT, et al. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Ann Rheum Dis. 2023 Aug 31:ard-2023-224731. doi:10.1136\/ard-2023-224731.","journal-title":"Ann Rheum Dis. 2023 Aug"},{"key":"ref10","first-page":"385","article-title":"Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment?","volume":"33","author":"Peiteado D","year":"2015","unstructured":"Peiteado D, Villalba A, Mart\u00edn-Mola E, de Miguel E. Reduction but not disappearance of Doppler signal after two years of treatment for gout. Do we need a more intensive treatment? Clin Exp Rheumatol. 2015;33:385\u201390.","journal-title":"Clin Exp Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1136\/annrheumdis-2020-217392","article-title":"Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study","volume":"79","author":"Hammer HB","year":"2020","unstructured":"Hammer HB, Karoliussen L, Terslev L, Haavardsholm EA, Kvien TK, Uhlig T. Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study. Ann Rheum Dis. 2020;79:1500\u20131505. doi: 10.1136\/annrheumdis-2020-217392.","journal-title":"Ann Rheum Dis"},{"issue":"SI","key":"ref12","doi-asserted-by":"publisher","first-page":"SI81-SI85","DOI":"10.1093\/rheumatology\/keab533","article-title":"Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study","volume":"61","author":"Uhlig T","year":"2022","unstructured":"Uhlig T, Eskild T, Karoliussen LF, Sexton J, Kvien TK, Haavardsholm EA, et al. Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. Rheumatology (Oxford). 2022;61(SI):SI81-SI85. doi: 10.1093\/rheumatology\/keab533.","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"113139","DOI":"10.1016\/j.celrep.2023.113139","article-title":"MSU crystal deposition contributes to inflammation and immune responses in gout remission","volume":"42","author":"Gu H","year":"2023","unstructured":"Gu H, Yu H, Qin L, Yu H, Song Y, Chen G, et al. MSU crystal deposition contributes to inflammation and immune responses in gout remission. Cell Rep. 2023;42:113139. doi:","journal-title":"Cell Rep"},{"key":"ref14","unstructured":"1016\/j.celrep.2023.113139."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-023-03098-4","article-title":"Interleukin-1\u03b2 inhibitors for the management of acute gout flares: a systematic literature review","volume":"25","author":"Schlesinger N","year":"2023","unstructured":"Schlesinger N, Pillinger MH, Simon LS, Lipsky PE. Interleukin-1\u03b2 inhibitors for the management of acute gout flares: a systematic literature review. Arthritis Res Ther. 2023;25:128. doi:10.1186\/s13075-023-03098-4.","journal-title":"Arthritis Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/art.20386","article-title":"Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis","volume":"50","author":"Tramontini N","year":"2004","unstructured":"Tramontini N, Huber C, Liu-Bryan R, Terkeltaub RA, Kilgore KS. Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum. 2004;50:2633\u20139. doi:10.1002\/art.20386.","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0090-1229(82)90235-5","article-title":"Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface","volume":"24","author":"Russell IJ","year":"1982","unstructured":"Russell IJ, Mansen C, Kolb LM, Kolb WP. Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface. Clin Immunol Immunopathol. 1982;24:239\u201350. doi:10.1016\/0090-1229(82)90235-5.","journal-title":"Clin Immunol Immunopathol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty M","year":"2018","unstructured":"Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392:1403\u20131412. doi:10.1016\/S0140-6736(18)32158-5.","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Dalbeth N","year":"2017","unstructured":"Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, et al. Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017;69:2386\u20132395. doi: 10.1002\/art.40233.","journal-title":"Arthritis Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2100028","article-title":"Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management","volume":"1","author":"O'Dell JR","year":"2022","unstructured":"O'Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. NEJM Evid. 2022;1:10.1056\/evidoa2100028. doi: 10.1056\/evidoa2100028.","journal-title":"NEJM Evid"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1038\/ncomms7555","article-title":"Xanthine oxidoreductase regulates macrophage IL1\u03b2 secretion upon NLRP3 inflammasome activation","volume":"6","author":"Ives A","year":"2015","unstructured":"Ives A, Nomura J, Martinon F, et al. Xanthine oxidoreductase regulates macrophage IL1\u03b2 secretion upon NLRP3 inflammasome activation. Nat Commun. 2015;6:6555.","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/srep04554","article-title":"Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice","volume":"4","author":"Nomura J","year":"2014","unstructured":"Nomura J, Busso N, Ives A, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014;4:4554.","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e75527","DOI":"10.1371\/journal.pone.0075527","article-title":"Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK","volume":"8","author":"Nomura J","year":"2013","unstructured":"Nomura J, Busso N, Ives A, et al. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK. PLoS One. 2013;8:e75527.","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1038\/s41467-019-12565-z","article-title":"Targeted knock-in mice expressing the oxidase-fixed form of xanthine oxidoreductase favor tumor growth","volume":"10","author":"Kusano T","year":"2019","unstructured":"Kusano T, Ehirchiou D, Matsumura T, et al. Targeted knock-in mice expressing the oxidase-fixed form of xanthine oxidoreductase favor tumor growth. Nat Commun. 2019;10:4904.","journal-title":"Nat Commun"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41598-020-57784-3","article-title":"Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice","volume":"10","author":"Nishikawa T","year":"2020","unstructured":"Nishikawa T, Nagata N, Shimakami T, et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep. 2020;10:815.","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13075-022-02852-4","article-title":"Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes","volume":"24","author":"Guma M","year":"2022","unstructured":"Guma M, Dadpey B, Coras R, Mikuls TR, Hamilton B, Quehenberger O, et al. Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes. Arthritis Res Ther. 2022;24:175. doi: 10.1186\/s13075-022-02852-4.","journal-title":"Arthritis Res Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2100028","article-title":"Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management","volume":"1","author":"O'Dell JR","year":"2022","unstructured":"O'Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. NEJM Evid. 2022;1:10.1056\/evidoa2100028.","journal-title":"NEJM Evid"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi T","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789\u201398. doi: 10.1136\/annrheumdis-2015-208237.","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41380-021-01339-z","article-title":"Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia","volume":"27","author":"Campeau A","year":"2022","unstructured":"Campeau A, Mills RH, Stevens T, Rossitto LA, Meehan M, Dorrestein P, et al. Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia. Mol Psychiatry. 2022;27:1217\u20131225. doi: 10.1038\/s41380-021-01339-z.","journal-title":"Mol Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","author":"Terkeltaub R","unstructured":"Terkeltaub R. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review. Drugs. 2023 Oct 11. doi:10.1007\/s40265-023-01944-y. epub ahead of print.","DOI":"10.1007\/s40265-023-01944-y"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.cell.2020.07.040","article-title":"Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures","volume":"182","author":"Wozniak JM","year":"2020","unstructured":"Wozniak JM, Mills RH, Olson J, Caldera JR, Sepich-Poore GD, Carrillo-Terrazas M, et al. Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures. Cell. 2020;182:1311\u20131327.e14. doi: 10.1016\/j.cell.2020.07.040.","journal-title":"Cell."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/rheumatology\/kew337","article-title":"Genetic variants of PPAR-gamma coactivator 1B augment NLRP3-mediated inflammation in gouty arthritis","volume":"56","author":"Chang WC","year":"2017","unstructured":"Chang WC, Jan Wu YJ, Chung WH, et al. Genetic variants of PPAR-gamma coactivator 1B augment NLRP3-mediated inflammation in gouty arthritis. Rheumatology (Oxford). 2017;56:457\u2013466. doi: 10.1093\/rheumatology\/kew337.","journal-title":"Rheumatology (Oxford)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13075-015-0802-3","article-title":"Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout","volume":"17","author":"McKinney C","year":"2015","unstructured":"McKinney C, Stamp LK, Dalbeth N, et al. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Res Ther. 2015;17:288. doi: 10.1186\/s13075-015-0802-3.","journal-title":"Arthritis Res Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1469-1809.1996.tb01192.x","article-title":"The human complement C8G gene, a member of the lipocalin gene family: polymorphisms and mapping to chromosome 9q34.3","volume":"60","author":"Dewald G","year":"1996","unstructured":"Dewald G, Cichon S, Bryant SP, Hemmer S, N\u00f6then MM, Spurr NK. The human complement C8G gene, a member of the lipocalin gene family: polymorphisms and mapping to chromosome 9q34.3. Ann Hum Genet. 1996;60:281\u201391. doi:","journal-title":"Ann Hum Genet"},{"key":"ref35","unstructured":"1111\/j.1469-1809.1996.tb01192.x."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/annrheumdis-2015-207338","article-title":"Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome","volume":"75","author":"Cumpelik A","year":"2016","unstructured":"Cumpelik A, Ankli B, Zecher D, Schifferli JA. Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome. Ann Rheum Dis. 2016;75:1236\u201345. doi: 10.1136\/annrheumdis-2015-207338.","journal-title":"Ann Rheum Dis."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1038\/ncomms7574","article-title":"Vimentin regulates activation of the NLRP3 inflammasome","volume":"6","author":"Santos G","year":"2015","unstructured":"dos Santos G, Rogel MR, Baker MA, Troken JR, Urich D, Morales-Nebreda L, Et al. Vimentin regulates activation of the NLRP3 inflammasome. Nat Commun. 2015;6:6574. doi: 10.1038\/ncomms7574.","journal-title":"Nat Commun"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1038\/s41598-020-62727-z","article-title":"CD44 Receptor Mediates Urate Crystal Phagocytosis by Macrophages and Regulates Inflammation in A Murine Peritoneal Model of Acute Gout","volume":"10","author":"Bousoik E","year":"2020","unstructured":"Bousoik E, Qadri M, Elsaid KA. CD44 Receptor Mediates Urate Crystal Phagocytosis by Macrophages and Regulates Inflammation in A Murine Peritoneal Model of Acute Gout. Sci Rep. 2020;10:5748. doi:10.1038\/s41598-020-62727-z.","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/art.37822","article-title":"Neutrophil cannibalism triggers transforming growth factor \u03b21 production and self regulation of neutrophil inflammatory function in monosodium urate monohydrate crystal-induced inflammation in mice","volume":"65","author":"Steiger S","year":"2013","unstructured":"Steiger S, Harper JL. Neutrophil cannibalism triggers transforming growth factor \u03b21 production and self regulation of neutrophil inflammatory function in monosodium urate monohydrate crystal-induced inflammation in mice. Arthritis Rheum. 2013;65:815\u201323. doi: 10.1002\/art.37822.","journal-title":"Arthritis Rheum"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cytogfr.2005.09.007","article-title":"Cross-talk between IGF-I and TGF-beta signaling pathways","volume":"17","author":"Danielpour D","year":"2006","unstructured":"Danielpour D, Song K. Cross-talk between IGF-I and TGF-beta signaling pathways. Cytokine Growth Factor Rev. 2006;17:59\u201374. doi:10.1016\/j.cytogfr.2005.09.007.","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"109139","DOI":"10.1016\/j.clim.2022.109139","article-title":"CXCL7 aggravates the pathological manifestations of neuromyelitis optica spectrum disorder by enhancing the inflammatory infiltration of neutrophils, macrophages and microglia","volume":"2022245","author":"Liu Z","unstructured":"Liu Z, Wang Y, Ding Y, Wang H, Zhang J, Wang H. CXCL7 aggravates the pathological manifestations of neuromyelitis optica spectrum disorder by enhancing the inflammatory infiltration of neutrophils, macrophages and microglia. Clin Immunol. 2022245:109139. doi: 10.1016\/j.clim.2022.109139.","journal-title":"Clin Immunol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e0151509","DOI":"10.1371\/journal.pone.0151509","article-title":"Lactoferrin Is an Allosteric Enhancer of the Proteolytic Activity of Cathepsin G","volume":"1","author":"Eipper S","year":"2016","unstructured":"Eipper S, Steiner R, Lesner A, Sienczyk M, Palesch D, Halatsch ME, et al. Lactoferrin Is an Allosteric Enhancer of the Proteolytic Activity of Cathepsin G. PLoS One. 2016;1:e0151509. doi: 10.1371\/journal.pone.0151509.","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/art.42413","article-title":"Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia","volume":"75","author":"Elsaid K","year":"2023","unstructured":"Elsaid K, Merriman TR, Rossitto LA, Liu-Bryan R, Karsh J, Phipps-Green A, et al. Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia. Arthritis Rheumatol. 2023;75:794\u2013805. doi: 10.1002\/art.42413.","journal-title":"Arthritis Rheumatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1524-475X.2009.00457.x","article-title":"Circulating monocytes have the capacity to be transdifferentiated into keratinocyte-like cells","volume":"17","author":"Medina A","year":"2009","unstructured":"Medina A, Brown E, Carr N, Ghahary A. Circulating monocytes have the capacity to be transdifferentiated into keratinocyte-like cells. Wound Repair Regen. 2009;17:268\u201377. doi: 10.1111\/j.1524-475X.2009.00457.x.","journal-title":"Wound Repair Regen"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41573-019-0025-4","article-title":"Therapeutic targeting of trained immunity","volume":"18","author":"Mulder WJM","year":"2019","unstructured":"Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG. Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019;18:553\u2013566. doi:10.1038\/s41573-019-0025-4.","journal-title":"Nat Rev Drug Discov"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/rheumatology\/kes326","article-title":"Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout","volume":"52","author":"Grainger R","year":"2013","unstructured":"Grainger, R, McLaughlin J, Harrison AA, Harper JL. Hyperuricaemia elevates circulating CCL2 levels and primes monocyte trafficking in subjects with inter-critical gout, Rheumatology, 2013;52:1018\u20131021. doi:10.1093\/rheumatology\/kes326.","journal-title":"Rheumatology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1073\/pnas.1620910114","article-title":"Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway","volume":"114","author":"Cri\u015fan TO","year":"2017","unstructured":"Cri\u015fan TO, Cleophas MCP, Novakovic B, Erler K, van de Veerdonk FL, Stunnenberg HG, et al. Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. Proc Natl Acad Sci U S A. 2017;114:5485\u20135490. doi: 10.1073\/pnas.1620910114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"107909","DOI":"10.1016\/j.isci.2023.107909","article-title":"Hyperuricemia remodels the serum proteome toward a higher inflammatory state","volume":"26","author":"Cab\u0103u G","year":"2023","unstructured":"Cab\u0103u G, Gaal O, Badii M, Nica V, Mirea AM, Hotea I, et al Hyperuricemia remodels the serum proteome toward a higher inflammatory state. iScience. 2023;26:107909. doi: 10.1016\/j.isci.2023.107909.","journal-title":"iScience"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/ATVBAHA.118.311022","article-title":"Human Monocyte Heterogeneity as Revealed by High-Dimensional Mass Cytometry","volume":"39","author":"Hamers AAJ","year":"2019","unstructured":"Hamers AAJ, Dinh HQ, Thomas GD, Marcovecchio P, Blatchley A, Nakao CS, et al. Human Monocyte Heterogeneity as Revealed by High-Dimensional Mass Cytometry. Arterioscler Thromb Vasc Biol. 2019;39:25\u201336. doi: 10.1161\/ATVBAHA.118.311022.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 1","key":"ref50","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/geroni\/igaa057.3146","volume":"4","author":"Haynes L","year":"2020","unstructured":"Haynes L. Immunological Heterogeneity. Innov Aging. 2020;4(Suppl 1):855. doi: 10.1093\/geroni\/igaa057.3146.","journal-title":"Innov Aging"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/oby.23632","article-title":"Immunomodulatory effects of colchicine on peripheral blood mononuclear cell subpopulations in human obesity: Data from a randomized controlled trial","volume":"31","author":"Patel TP","year":"2023","unstructured":"Patel TP, Levine JA, Elizondo DM, Arner BE, Jain A, Saxena A, et al. Immunomodulatory effects of colchicine on peripheral blood mononuclear cell subpopulations in human obesity: Data from a randomized controlled trial. Obesity (Silver Spring). 2023;31:466\u2013478. doi:","journal-title":"Obesity (Silver Spring)"},{"key":"ref52","unstructured":"1002\/oby.23632."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12953-021-00180-0","article-title":"Quantitative proteomics by iTRAQ-PRM based reveals the new characterization for gout","volume":"19","author":"Chen G","year":"2021","unstructured":"Chen G, Cheng J, Yu H, Huang X, Bao H, Qin L, et al. Quantitative proteomics by iTRAQ-PRM based reveals the new characterization for gout. Proteome Sci. 2021;19:12. doi: 10.1186\/s12953-021-00180-0.","journal-title":"Proteome Sci"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3770277\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3770277\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T19:30:51Z","timestamp":1711567851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3770277\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":53,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3770277\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,1,2]]},"subtype":"preprint"}}